6PPD metabolic activation by CYP3A initiates cytotoxicity in mouse primary hepatocytes
Archives of Toxicology · 2026-09 · 100 (9) · 4003-4019
DOI: 10.1007/s00204-026-04438-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 20.05.2026. Verfasst von Yao Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. Hauptthemen laut MEDLINE: Hepatocytes, Cytochrome P-450 CYP3A, Phenylenediamines, Environmental Pollutants. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
N-(1,3-Dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD) is a widely used rubber antioxidant and an emerging environmental pollutant, yet its hepatotoxic potential and the underlying role of metabolic activation remain poorly understood. Here, we integrated metabolite profiling, liver microsomal incubations, chemical oxidation synthesis, and mouse primary hepatocytes and animal exposure to examine the metabolic and toxicological outcomes of 6PPD. A total of 54 metabolites were identified in mice, including phase I oxidation products and phase II conjugates. Importantly, the reactive metabolite p-benzoquinone diimide (6PPD-QDI) was detected and shown to form conjugates with biological thiols. In microsomal incubations containing glutathione (GSH), N-acetylcysteine (NAC), or cysteine conjugates, 6PPD produced the corresponding conjugates, supporting the generation of 6PPD-QDI. The conjugate formation was NADPH-dependent and substantially suppressed by the CYP3A inhibitor ketoconazole, indicating that CYP3A mediates the bioactivation of 6PPD. In vivo, identical GSH and NAC conjugates were detected in bile and urine of exposed mice, and hepatic proteins contained dose-dependent protein adduction at cysteine residues. In primary hepatocytes, 6PPD induced concentration- and time-dependent cytotoxicity associated with GSH depletion and protein adduction, which was mitigated by CYP3A inhibition or thiol supplementation. Notably, CYP3A4-overexpressing HepG2 cells exhibited enhanced susceptibility to cytotoxicity and protein adduction compared to wild-type cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China.
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Educati…
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China. huzixia@syphu.edu.cn.
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. yingpeng1999@163.com.
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. zhengjiang@syphu.edu.cn.
ORCID-Profile: Jiang Zheng
Zitieren
APA
Sun, Y., Zheng, J., Zhao, Y., Li, W., Hu, Z., Peng, Y., & Zheng, J. (2026). 6PPD metabolic activation by CYP3A initiates cytotoxicity in mouse primary hepatocytes. Archives of Toxicology, 100(9), 4003-4019. https://doi.org/10.1007/s00204-026-04438-4
Vancouver
Sun Y, Zheng J, Zhao Y, Li W, Hu Z, Peng Y, et al. 6PPD metabolic activation by CYP3A initiates cytotoxicity in mouse primary hepatocytes. Archives of Toxicology. 2026;100(9):4003-4019. doi:10.1007/s00204-026-04438-4
BibTeX
@article{Sun2026,
author = {Sun, Yao and Zheng, Jiannan and Zhao, Yanjia and Li, Weiwei and Hu, Zixia and Peng, Ying and Zheng, Jiang},
title = {6PPD metabolic activation by CYP3A initiates cytotoxicity in mouse primary hepatocytes},
journal = {Archives of Toxicology},
year = {2026},
volume = {100},
number = {9},
pages = {4003--4019},
doi = {10.1007/s00204-026-04438-4}
}
EUVIMED